Clinical trials: Neoplasms Recurrence
Small Cell Lung Cancer
Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
Small cell lung cancer (SCLC) is a chemotherapy and radiotherapy sensitive tumor, but with very high rates of relapse and metastasis, resulting in a very poor outcome.
- Trial name
- NCT01173523
- Testing
- STA-9090
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- David M. Jackman, MD
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the tumor.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00397488
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Liver Metastases, Colorectal Neoplasms
Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases
The purpose of the study is to assess the overall survival and progression free survival of patients treated with Litx™ + chemotherapy versus chemotherapy alone in the treatment of Colorectal Cancer with recurrent liver…
- Conditions
- Liver Metastases, Colorectal Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local
- Trial name
- NCT00440310
- Testing
- Talaporfin sodium, Percutaneous placement of device in liver metastases, Interstitial light emitting diodes
- Where
- 57 sites in Austria, Bosnia and Herzegovina and 11 more
- Volunteers
- 483 people
- Sponsor
- Light Sciences Oncology
Osteosarcoma, Osteosarcoma Recurrent
Olaparib With Ceralasertib in Recurrent Osteosarcoma
This study is being done in order to evaluate the effectiveness of using two drugs (olaparib and ceralasertib) to treat patients with osteosarcoma that has not responded to treatment or has come back after treatment The names of…
- Trial name
- NCT04417062
- Testing
- Olaparib, Ceralasertib
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Dana-Farber Cancer Institute
Hematologic Malignancies, Relapse
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
The investigators hypothesize that adding carfilzomib to standard conditioning regimen for allo-HCT for advanced or high-risk hematologic malignancies will decrease post-transplant relapse and treatment-related mortality by…
- Conditions
- Hematologic Malignancies, Relapse, Graft-Versus-Host Disease
- Trial name
- NCT02145403
- Testing
- Carfilzomib, Tacrolimus
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Michigan Rogel Cancer Center
Estrogen Receptor Negative, Estrogen Receptor Positive
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
This randomized phase III trial studies the side effects and how well different chemotherapy regimens with or without bevacizumab work in treating patients with stage IIIC or stage IV breast cancer.
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT00785291
- Testing
- Bevacizumab, Ixabepilone, Laboratory Biomarker Analysis
- Where
- 704 sites in United States, Puerto Rico
- Volunteers
- 799 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Skin Carcinoma, Skin Squamous Cell Carcinoma
Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer
This phase II trial studies how well pembrolizumab works in treating patients with skin cancer that has spread from where it started to nearby tissue, lymph nodes, or other parts of the body.
- Trial name
- NCT02964559
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Emory University
Triple Negative Breast Cancer, Endometrial Cancer
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Background: The new drug ONC201 have been shown to kill breast cancer and endometrial cancer cells in the laboratory. The exact mechanism of action is not completely clear yet, but the ONC201 destroys the mitochondria inside the…
- Conditions
- Triple Negative Breast Cancer, Endometrial Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer
- Trial name
- NCT03394027
- Testing
- ONC201
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)
A single arm, open label, prospective, phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at…
- Trial name
- ReGaiN (NCT00824746)
- Testing
- Gefitinib retreatment
- Where
- South Korea
- Volunteers
- 23 people
- Sponsor
- Chonnam National University Hospital
Recurrent Breast Cancer, Stage IV Breast Cancer
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer
Phase II trial to study the effectiveness of combination chemotherapy with or without trastuzumab in treating women who have metastatic breast cancer.
- Trial name
- NCT00004888
- Testing
- pegylated liposomal doxorubicin hydrochloride, docetaxel, trastuzumab
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma
This phase I/II trial studies the side effects and best dose of vaccine therapy when given with or without cyclophosphamide and to see how well they work in treating patients with multiple myeloma that has come back (recurrent)…
- Trial name
- NCT00450814
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Mayo Clinic
Liver Cancer
Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00524316
- Testing
- doxorubicin hydrochloride, sunitinib malate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
Recurrent Uterine Sarcoma, Uterine Carcinosarcoma
Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus
This phase II trial is studying how well temsirolimus works in treating patients with recurrent or persistent cancer of the uterus.
- Trial name
- NCT01061606
- Testing
- temsirolimus
- Where
- 20 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
This phase II trial studies how well dasatinib works in treating patients with glioblastoma multiforme or gliosarcoma that has come back.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Trial name
- NCT00423735
- Testing
- Dasatinib, Pharmacological Study
- Where
- 188 sites in United States, Canada and 1 more
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
This phase III trial studies how well radiation therapy with protons works compared with photons in treating patients with liver cancer.
- Conditions
- Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Unresectable Hepatocellular Carcinoma
- Trial name
- NCT03186898
- Testing
- Proton Therapy, Photon Therapy
- Where
- 27 sites in United States
- Volunteers
- 116 people
- Sponsor
- NRG Oncology
Malignant Glioma
Study of Capecitabine to Treat Recurrent High Grade Gliomas
The purpose of this study is to determine if capecitabine is effective in the treatment of high grade gliomas that have returned after completing treatment.
- Trial name
- NCT00717197
- Testing
- Capecitabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Florida
Colorectal Cancer
A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)
The purpose of this study was to determine the activity of two doses of robatumumab (SCH 717454, MK-7454) in participants with relapsed or recurrent colorectal cancer.
- Trial name
- NCT00551213
- Testing
- Robatumumab, Irinotecan, Cetuximab
- Volunteers
- 67 people
- Sponsor
- Merck Sharp & Dohme LLC
Adenocarcinoma of the Esophagus
Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus
Current therapies for Adenocarcinoma of the Esophagus provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Adenocarcinoma of the…
- Trial name
- NCT00003487
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Burzynski Research Institute
Recurrent Melanoma, Stage IV Skin Melanoma
Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
This randomized phase II trial is studying giving bevacizumab together with interferon alpha to see how well it works compared to giving bevacizumab alone in treating patients with metastatic malignant melanoma.
- Trial name
- NCT00026221
- Testing
- Recombinant Interferon Alfa, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer
Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy
Drugs used in chemotherapy, such as rebeccamycin analog, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
- Trial name
- NCT00084487
- Testing
- becatecarin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.